Maintenance of efficacy from Week 16 to Week 52a.
| Variables | GOL 2 mg/kg |
|---|---|
| Patients randomized, n | 105 |
| Week 16 responders with response at Week 52, n/N (%) | |
| ASAS20 | 63/77 (81.8) |
| ASAS40 | 45/50 (90.0) |
| BASDAI50 | 38/43 (88.4) |
| ASDAS inactive disease | 15/21 (71.4) |
↵a Missing data were imputed using last observation carried forward. For dichotomous composite endpoints with all components missing, non-responder imputation was used through Week 52. GOL: golimumab; ASAS20/40: ≥ 20%/40% improvement in Assessment of SpondyloArthritis international Society criteria; ASDAS: Ankylosing Spondylitis Disease Activity Score; BASDAI50: 50% improvement in Bath Ankylosing Spondylitis Disease Activity Index.